The role and therapeutic implications of RING-finger E3 ubiquitin ligases in hepatocellular carcinoma

Int J Cancer. 2015 Jan 15;136(2):249-57. doi: 10.1002/ijc.28717. Epub 2014 Jan 27.

Abstract

Increasing evidence indicates that deregulation of RING-finger ubiquitin-protein ligases (E3s) involves in the development of hepatocellular carcinoma (HCC). These RING-finger E3s serve as oncoproteins or tumor suppressors in HCC under specific conditions. In this review, we summarize current knowledge about abnormal RING-finger E3s and their clinical significance in the development of HCC, and discuss parts of critical substrates for these RING-finger E3s in detail. Furthermore, in light of success of Bortezomib in treating hematological malignancies, we describe the preclinical and clinical studies of therapeutic approaches targeting aberrant RING-finger E3s in HCC.

Keywords: RING-finger E3 ubiquitin ligase; hepatocellular carcinoma; therapeutic target.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Carcinoma, Hepatocellular / drug therapy*
  • Carcinoma, Hepatocellular / enzymology
  • Humans
  • Liver Neoplasms / drug therapy*
  • Liver Neoplasms / enzymology
  • Molecular Targeted Therapy
  • Proteasome Endopeptidase Complex / drug effects*
  • RING Finger Domains
  • Ubiquitin-Protein Ligases / antagonists & inhibitors*
  • Ubiquitin-Protein Ligases / metabolism

Substances

  • Antineoplastic Agents
  • Ubiquitin-Protein Ligases
  • Proteasome Endopeptidase Complex